BioAge develops a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging by using its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records tracking individuals over the lifespan, to map out the key molecular pathways that impact healthy human aging.

Buy or sell BioAge stockLearn more about BioAge IPO

OverviewFinancingsValuation

Enterprise Value

Access BioAge’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like BioAge.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Animation displayed is not current and securities are shown for illustrative purposes only.

BioAge investors also invested in these private companies

Redpoint Ventures

Stripe, Arctic Wolf, BioAge, Whatnot, Cribl, Alchemy, Wealthsimple, Next Insurance, PsiQ, Orca Security

Andreessen Horowitz

Databricks, Anduril, Ripple, Zipline, Stripe, Flock Safety, Shield AI, Fanatics, Skydio, Applied Intuition

Khosla Ventures

OpenAI, Rubrik, Stripe, Synchron, Varda Space Industries, Eat Just, Impossible Foods, ZocDoc, BioAge, Vectra AI

Ra Capital Management

X-energy, BioAge, Boundless Bio, Freenome, Capstan Therapeutics, Synthego, FogPharma, Mindtickle, Sortera Alloys, Septerna

AME Cloud Ventures

Eat Just, BioAge, Docker, Mythic, Mojo Vision, Illumio, Vectra AI, BitPay, Tango, Cohere Technologies

Longitude Capital

BioAge, Quanta Therapeutics, Cohere Health, Dascena, Nalu Medical, Nalu

Caffeinated Capital

Notion, BioAge, Virta Health, Brex, Mercury, SingleStore (MemSQL), Front, Bolt Financial, Color, Loft

Bossanova Investimentos

SpinLaunch, Axiom Space, BioAge, Plume, Hotmart, Bending Spoons, Property Finder, JumpCloud, Petal, Array

Felicis

Canva, Crusoe, Gusto, BioAge, Runway, Coalition, Sourcegraph, Crunchbase, HyperScience, Guideline

Cormorant Asset Management

BioAge, FogPharma, Bigfoot Biomedical, Orionis Biosciences, Ensoma, Alumis, Myra Vision, Neurona Therapeutics, Star Therapeutics, Supira Medical

Pear VC

BioAge, Nightfall AI, Branch Metrics, One Concern

Green Sands Equity

Synchron, USA Rare Earth, BioAge, Devoted Health, Fizz, Commure

Sofinnova Investments

BioAge, Capstan Therapeutics, Quanta Therapeutics, RayzeBio, Antiva Biosciences, Chroma Medicine, Star Therapeutics, OnCusp Therapeutics

RTW Investments

BioAge, Beta Bionics, Acelyrin, Apogee Therapeutics, Mineralys

Sands Capital

BioAge, Ramp, StockX, Freenome, Upgrade, Klaviyo, RayzeBio, Alamar Biosciences, Globalization Partners, Hashtag Paid

Osage University Partners

BioAge, Menlo Security, Delfi Diagnostics, Censys, Verve Motion, Quantum Circuits, Chroma Medicine, Brimstone

OrbiMed

BioAge, Caris Life Sciences, Capstan Therapeutics, Iambic Therapeutics, Delfi Diagnostics, Sionna Therapeutics, Apogee Therapeutics, Acelyrin, RayzeBio, ADARx Pharmaceuticals

Summit Peak Investments

Notion, BioAge, Virta Health, ClassDojo, Route, SingleStore (MemSQL), Imubit, Navan, AgentSync, Settle

CSC UpShot Ventures

Triller, Notion, Gecko Robotics, BioAge, May Mobility, Maven, Nav, Kin Insurance, Side, Athelas

Pivotal bioVenture Partners

BioAge, Evommune

Summer VC

OURA, BioAge, Parsley Health

Amgen

BioAge, Casma Therapeutics, Hummingbird Bioscience, Carmot Therapeutics, Generate Biomedicines

AARP Foundation

BioAge

Springboard Enterprises

BioAge

Team

Management Team

Kristen Fortney Ph.D

Co-Founder & Chief Executive Officer

Eric Morgen MD

Co-Founder & Chief Operating Officer

BJ Sullivan Ph.D

Chief Strategy Officer

Ann Neale

Chief Development Officer

Peng Leong Ph.D

Chief Business Officer & Therapeutic Area Head, Brain Aging

Paul Rubin MD

Chief Medical Officer & Executive Vice President of Research

Dov Goldstein MD

Chief Financial Officer

Board Members

James Healy Ph.D

Sofinnova Investments

Vijay Pande Ph.D

Andreessen Horowitz

Frequently Asked Questions About BioAge’s Stock

Can you buy BioAge’s stock?

BioAge is not publicly traded on NYSE or NASDAQ in the U.S. To buy BioAge’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Can you sell BioAge’s stock?

Yes, you can sell stock of a private company like BioAge. Forge can help you sell your BioAge stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.

What is BioAge’s stock price?

BioAge is a privately held company and therefore does not have a public stock price. However, you may access BioAge’s private market stock price with Forge Data.

What is BioAge’s stock ticker symbol?

BioAge does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Fierce Biotech 02/13/2024

GLP-1 enthusiasm pushes BioAge Labs into new age with $170M series D

Until last year, BioAge Labs' progress could be best described as a slow burn, with a pipeline of longevity-focused medicines taking shape incrementally but consistently. The frenzy around GLP-1s changed all of that, with BioAge’s profile ascending dramatically thanks to being one of a select few biotechs with a combo candidate that might enhance weight loss without muscle loss. Equipped with that potential, and a partnership with Eli Lilly to test the hypothesis, BioAge has closed a $170 million series D led by Sofinnova with contributions from major institutional biotech investors and the venture arms of both the Indianapolis pharma and Amgen.

Reuters 02/13/2024

Eli Lilly partner BioAge raises $170 mln for obesity treatment

BioAge Labs, a biotech startup collaborating with Eli Lilly (LLY.N), opens new tab for trialing its obesity therapy, said on Tuesday it had raised $170 million in its latest funding round.

Frequently Asked Questions

Updated on: Apr 19, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

BioAge Stock

Register To Buy and Sell Shares

Enterprise Value

Access BioAge’s valuation and stock price.

BioAge investors also invested in these private companies

Team

Management Team

Board Members

Frequently Asked Questions About BioAge’s Stock

Other companies like BioAge in the BioTech & Pharma sector

Egenesis

Colossal Biosciences

Precision Neuroscience

Altos Labs

Tempus

Life Biosciences

Pendulum Therapeutics

Cytonics

Resilience

News Highlights

Frequently Asked Questions

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

BioAge Stock

Register To Buy and Sell Shares

Enterprise Value

Access BioAge’s valuation and stock price.

BioAge investors also invested in these private companies

Team

Management Team

Board Members

Frequently Asked Questions About BioAge’s Stock

Other companies like BioAge in the BioTech & Pharma sector

Egenesis

Colossal Biosciences

Precision Neuroscience

Altos Labs

Tempus

Life Biosciences

Pendulum Therapeutics

Cytonics

Resilience

News Highlights

Trending Companies

Frequently Asked Questions

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES